| 引用本文:宋琪1，夏义欣1，路泽军2，赵春艳1，张卓梅1，陈琳1，刘红1.多柔比星脂质体联合复方红豆杉胶囊治疗晚期铂类耐药型卵巢癌的临床效果[J].世界中医药,2018,(02):. |
|
| 多柔比星脂质体联合复方红豆杉胶囊治疗晚期铂类耐药型卵巢癌的临床效果 |
| Clinical Study of Liposomal Doxorubicin Combined with Hongdoushan Capsule in the Treatment of Advanced Platinum Resistant Ovarian Cancer |
| 投稿时间：2016-02-24 |
| DOI：10.3969/j.issn.1673-7202.2018.02.029 |
| 中文关键词: 多柔比星脂质体 复方红豆杉胶囊 顺铂 卡铂 卵巢癌 |
| English Keywords:Liposomal doxorubicin Hongdoushan capsule Cisplatin Carboplatin Ovarian cancer |
| 基金项目:中国人民解放军海军总医院创新培育基金项目(CXPY201503) |
|
| 摘要点击次数: 789 |
| 全文下载次数: 981 |
| 中文摘要: |
| 目的:探讨脂质体多柔比星联合复方红豆杉胶囊治疗难治复发的铂类药物耐药的卵巢癌患者的临床效果及不良反应。方法：选取行紫杉醇联合顺铂或卡铂化疗37例复发性铂类药物耐药的卵巢癌患者，复发后随机分为观察组（多柔比星脂质体联合复方红豆杉胶囊治疗）20例，对照组（单药多柔比星脂质体治疗）17例，方案为：多柔比星脂质体(30～40 mg/m2静脉滴注)，复方红豆杉胶囊,2粒/次,口服，3次/d,共15 d，每3周为1个周期;评价临床疗效及不良反应，监测患者化疗前后心电图、心肌酶谱、左心室射血分数的变化，以进一步评估多柔比星脂质体的心脏毒性。结果：联合复方红豆杉胶囊有效率为35.00%,单药组为23.53%,差异有统计学意义(P<0.05)。观察组疾病控制率为75%，对照组为58.82%，差异有统计学意义(P<0.05);观察组KPS评分改善优于对照组(65%比47.06%,P<0.05)。2组均未出现心脏毒性反应。主要不良反应为血液学毒性和胃肠道反应。其中观察组无Ⅲ～Ⅳ度血液学毒性和胃肠道反应发生;2组Ⅰ～Ⅱ度血液学毒性发生率为30.00%比29.41%,Ⅰ～Ⅱ度胃肠道反应发生率为60.00%比47.06%。差异无统计学意义(P>0.05)。结论:对于顺铂或卡铂耐药型卵巢癌患者，多柔比星脂质体联合复方红豆杉胶囊疗效优于单药多柔比星脂质体，且不良反应轻，生命质量获益明显，有良好耐受性。 |
| English Summary: |
| To analyze the effectiveness of liposomal doxorubicin combined with Hongdoushan capsule in the treatment of advanced platinum resistant ovarian cancer. Methods:A total of 37 patients with advanced platinum resistant ovarian cancer were divided into combined group (20 cases) and single drug group (17 cases). The combination group was given the treatment of liposomal doxorubicin (30～40 mg/m2 intravenously) and Hongdoushan capsule (0.6 g 3/d), and the single drug group was given the treatment of liposomal doxorubicin alone. The short-term efficacy and toxicity were evaluated. ECG, left ventricular ejection fraction, myocardial enzyme changes were monitored to evaluate cardiac toxicity of liposomal doxorubicin. Results:Efficacy rate was 35% in combined group and 23.53% in single group. There was statistical significance between the two groups (P<0.05). The control rate for disease was higher in combined group than the single group, and there was statistical significance between the two groups (P<0.05). KPS score of the combined treatment group improved significantly better than the control group (65% vs 47.06%). The incidences of nausea, vomiting, diarrhea and skin rash, dysfunction of hepatic function in the combined group were higher than the single drug group, while there were no differences between the two groups (P>0.05). Conclusion:Liposomal doxorubicin combined with Hongdoushan capsules in the treatment of advanced platinum resistant ovarian cancer has better clinical benefits and improvement for the quality of life than the single group. The therapy method is worthy to be popularized. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
